Cancer Biology & Therapy · 2015 · 44 citations · 35 references
MedicineMolecular BiologyOncologyCarcinogenesisMolecular OncologyTumor ProgressionCancer Cell SignalingCancer GenomicsCancer ProgressionEpithelial-mesenchymal TransitionEpithelial-to-mesenchymal TransitionSquamous Cell CarcinomaCetuximab TherapyEgfr InhibitionEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersHomozygous DeletionHuman Papillomavirus StatusSmad Signaling PathwayTumor Cell Motility
Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) and cetuximab, a monoclonal antibody targeting this receptor, is widely used to treat these patients. In the following investigation, we examined the role of SMAD4 down-regulation in mediating epithelial-to-mesenchymal transition (EMT) and cetuximab resistance in HNSCC. We determined that SMAD4 downregulation was significantly associated with increased cell motility, increased expression of vimentin, and cetuximab resistance in HNSCC cell lines. In the HNSCC genomic dataset obtained from The Cancer Genome Atlas, SMAD4 was altered in 20/279 (7%) of HNSCC via homozygous deletion, and nonsense, missense, and silent mutations. When SMAD4 expression was compared with respect to human papillomavirus (HPV) status, HPV-positive tumors had higher expression compared to HPV-negative tumors. Furthermore, higher SMAD4 expression also correlated with higher CDKN2A (p16) expression. Our data suggest that SMAD4 down-regulation plays an important role in the induction of EMT and cetuximab resistance. Patients with higher SMAD4 expression may benefit from cetuximab use in the clinic.
35
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang, Jonathan Harris, Richard Wheeler et al. · New England Journal of Medicine · 2010 · 6.5K citations · Full text
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text
Comprehensive genomic characterization of head and neck squamous cell carcinomas